The diagnostic value of circulating tumor DNA in hepatitis B virus induced hepatocellular carcinoma: a systematic review and meta-analysis.

Journal of Liver Cancer Pub Date : 2022-09-01 Epub Date: 2022-09-29 DOI:10.17998/jlc.2022.09.19

Young Chang, Soung Won Jeong, Jae Young Jang, Hyuksoo Eun, Young-Sun Lee, Do Seon Song, Su Jong Yu, Sae Hwan Lee, Won Kim, Hyun Woong Lee, Sang Gyune Kim, Seongho Ryu, Suyeon Park

{"title":"The diagnostic value of circulating tumor DNA in hepatitis B virus induced hepatocellular carcinoma: a systematic review and meta-analysis.","authors":"Young Chang, Soung Won Jeong, Jae Young Jang, Hyuksoo Eun, Young-Sun Lee, Do Seon Song, Su Jong Yu, Sae Hwan Lee, Won Kim, Hyun Woong Lee, Sang Gyune Kim, Seongho Ryu, Suyeon Park","doi":"10.17998/jlc.2022.09.19","DOIUrl":null,"url":null,"abstract":"Background/aim: New biomarkers are urgently needed to aid in the diagnosis of early stage hepatocellular carcinoma (HCC). We performed a meta-analysis on the diagnostic utility of circulating tumor DNA (ctDNA) levels in patients with hepatitis B virus-induced HCC.Methods: We retrieved relevant articles from PubMed, Embase, and the Cochrane Library up to February 8, 2022. Two subgroups were defined; one subset of studies analyzed the ctDNA methylation status, and the other subset combined tumor markers and ctDNA assays. Pooled sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the summary receiver operating characteristic curve (AUC) were analyzed.Results: Nine articles including 2,161 participants were included. The overall SEN and SPE were 0.705 (95% confidence interval [CI], 0.629-0.771) and 0.833 (95% CI, 0.769-0.882), respectively. The DOR, PLR, and NLR were 11.759 (95% CI, 7.982-17.322), 4.285 (95% CI, 3.098-5.925), and 0.336 (0.301-0.366), respectively. The ctDNA assay subset exhibited an AUC of 0.835. The AUC of the combined tumor marker and ctDNA assay was 0.848, with an SEN of 0.761 (95% CI, 0.659-0.839) and an SPE of 0.828 (95% CI, 0.692-0.911).Conclusions: Circulating tumor DNA has promising diagnostic potential for HCC. It can serve as an auxiliary tool for HCC screening and detection, especially when combined with tumor markers.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 2","pages":"167-177"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/69/a4/jlc-2022-09-19.PMC10035733.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Liver Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17998/jlc.2022.09.19","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/9/29 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: New biomarkers are urgently needed to aid in the diagnosis of early stage hepatocellular carcinoma (HCC). We performed a meta-analysis on the diagnostic utility of circulating tumor DNA (ctDNA) levels in patients with hepatitis B virus-induced HCC.

Methods: We retrieved relevant articles from PubMed, Embase, and the Cochrane Library up to February 8, 2022. Two subgroups were defined; one subset of studies analyzed the ctDNA methylation status, and the other subset combined tumor markers and ctDNA assays. Pooled sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the summary receiver operating characteristic curve (AUC) were analyzed.

Results: Nine articles including 2,161 participants were included. The overall SEN and SPE were 0.705 (95% confidence interval [CI], 0.629-0.771) and 0.833 (95% CI, 0.769-0.882), respectively. The DOR, PLR, and NLR were 11.759 (95% CI, 7.982-17.322), 4.285 (95% CI, 3.098-5.925), and 0.336 (0.301-0.366), respectively. The ctDNA assay subset exhibited an AUC of 0.835. The AUC of the combined tumor marker and ctDNA assay was 0.848, with an SEN of 0.761 (95% CI, 0.659-0.839) and an SPE of 0.828 (95% CI, 0.692-0.911).

Conclusions: Circulating tumor DNA has promising diagnostic potential for HCC. It can serve as an auxiliary tool for HCC screening and detection, especially when combined with tumor markers.

Abstract Image

查看原文本刊更多论文

循环肿瘤 DNA 在乙型肝炎病毒诱发的肝细胞癌中的诊断价值：系统回顾和荟萃分析。

背景/目的：迫切需要新的生物标志物来帮助诊断早期肝细胞癌（HCC）。我们对乙肝病毒引起的 HCC 患者的循环肿瘤 DNA（ctDNA）水平的诊断效用进行了一项荟萃分析：我们从PubMed、Embase和Cochrane图书馆检索了截至2022年2月8日的相关文章。我们定义了两个亚组：一个研究亚组分析了ctDNA甲基化状态，另一个亚组结合了肿瘤标志物和ctDNA检测。对汇总灵敏度（SEN）、特异性（SPE）、阳性似然比（PLR）、阴性似然比（NLR）、诊断几率比（DOR）和汇总接收者操作特征曲线下面积（AUC）进行了分析：结果：共纳入 9 篇文章，2 161 名参与者。总体 SEN 和 SPE 分别为 0.705（95% 置信区间 [CI]，0.629-0.771）和 0.833（95% CI，0.769-0.882）。DOR、PLR和NLR分别为11.759（95% CI，7.982-17.322）、4.285（95% CI，3.098-5.925）和0.336（0.301-0.366）。ctDNA检测子集的AUC为0.835。肿瘤标志物和ctDNA联合检测的AUC为0.848，SEN为0.761（95% CI，0.659-0.839），SPE为0.828（95% CI，0.692-0.911）：循环肿瘤 DNA 具有诊断 HCC 的潜力。结论：循环肿瘤 DNA 具有诊断 HCC 的潜力，可作为筛查和检测 HCC 的辅助工具，尤其是与肿瘤标记物结合使用时。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Liver Cancer

自引率

0.00%

发文量